Vaccination with the up to date COVID-19 mRNA vaccine containing the extreme acute respiratory syndrome coronavirus-2 omicron JN.1 lineage was not related to an elevated threat for 29 opposed occasions, in response to a research printed on-line July 28 in JAMA Community Open.
Niklas Worm Andersson, M.D., Ph.D., from Statens Serum Institut in Copenhagen, Denmark, and colleagues examined the affiliation between vaccination with JN.1-containing vaccines and the danger for 29 critical opposed occasions tailored from prioritized lists of opposed occasions of particular curiosity to COVID-19 vaccines. End result charges throughout the first 28 days after JN.1-containing vaccine administration (i.e., the danger interval) had been in comparison with final result charges throughout the remaining interval.
Members had been adults in Denmark beneficial to obtain the 2024 to 2025 JN.1-containing booster vaccine who had beforehand acquired three or extra COVID-19 vaccine doses (1,012,400 people). The researchers discovered that throughout the 28-day threat interval after receipt of a JN.1-containing mRNA vaccine, there have been no important will increase within the fee of hospital contacts for any of 29 opposed occasions in contrast with reference interval charges.
The incidence fee ratios had been 0.84 (95% confidence interval [CI], 0.76 to 0.94), 0.92 (95% CI, 0.76 to 1.13), and 1.12 (95% CI, 0.41 to three.10) for ischemic cardiac occasions, intracranial bleeding, and myocarditis, respectively.
“Although we analyzed a nationwide cohort, some outcomes, such as erythema multiforme, occurred very rarely during follow-up, with consequently lower statistical precision, and some outcomes, such as transverse myelitis, could not be statistically compared,” the authors write.
Extra data:
Niklas Worm Andersson et al, Security of JN.1-Up to date mRNA COVID-19 Vaccines, JAMA Community Open (2025). DOI: 10.1001/jamanetworkopen.2025.23557
2025 HealthDay. All rights reserved.
Quotation:
COVID-19 mRNA vaccine focusing on omicron JN.1 lineage secure (2025, August 6)
retrieved 6 August 2025
from https://medicalxpress.com/information/2025-08-covid-mrna-vaccine-omicron-jn1.html
This doc is topic to copyright. Aside from any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for data functions solely.
